The U.S. Department of Energy's National Nuclear Security Administration has awarded NTP Radioisotopes, a unit of the Nuclear Energy Corporation of South Africa, a contract worth $25 million for the production of the medical isotope molybdenum-99 using low-enriched uranium. NTP Radioisotopes will be working with the Australian Nuclear Science and Technology Organisation in this initiative.
Health reform will shift U.S. health care spending, reducing Medicare costs and putting more money in the private sector, government analysts said. The law will likely slightly increase overall spending but will have the biggest effect on payers and providers. A separate study found most American adults remain confused about the health reform changes and when they are to begin.
Join ASNC on Sept. 23 for a special ASNC2010 session dedicated to government policies and regulations impacting nuclear cardiology. ASNC is pleased to welcome keynote speaker Alice G. Gosfield, Esq., who will present a lecture titled "Avoiding Marriage: Non-Acquisition Hospital-Physician Financial Strategies." This session also includes lectures from ASNC members on Medicare reimbursement, radiation reduction initiatives, health care reform and the ongoing isotope shortage, and is included as part of attendees' ASNC2010 registration.
Nuclear medicine experts are frustrated at the continued holdup of the American Medical Isotopes Production Act in the Senate. The delay is being caused by Sen. Kit Bond, R-Mo., who said the bill, which would support the domestic production of medical isotopes and cut off U.S. exports of highly enriched uranium, could endanger isotope supply in the country. "We don't think this is a bill that would cripple us," countered Dr. Michael Graham, past president of SNM. "It's a fairly unique opportunity for us to build a domestic isotope supply."
Ohio-based Cardinal Health is warning that shortages of technetium-99 could reach critically low levels for the remainder of May. Relief for the industry is in sight, however, with the Chalk River reactor in Ontario and the High Flux Reactor in Petten, Netherlands, slated to restart molybdenum-99 production in mid-summer.